Halozyme Therapeutics Inc (HALO) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Halozyme Therapeutics Inc   (NASDAQ: HALO)


Halozyme Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Halozyme Therapeutics Inc's ROI in the second quarter of 2026?
Halozyme Therapeutics Inc achieved a return on average invested assets (ROI) of 19.99 % in its second quarter of 2026, this is above HALO's average return on investment of -11.78%.
Halozyme Therapeutics Inc s investments during the 12 months ending in the second quarter of 2026 are valued at $2 billion

ROI has improved compared to 17.53% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 40 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 386, from total ROI ranking in the first quarter of 2026 at 393.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 4.75 % 1.86 % 2.92 % 1.37 % 13.75 %
Y / Y Net Income Change TTM -25.78 % -28.13 % -13.72 % 158.62 % 497.65 %
Investment (TTM) in Millions 2,233 2,310 2,348 1,384 1,920
Return On Investment (TTM) 19.99 % 17.53 % 16.47 % 32.75 % 28.22 %
HALO's Overall Ranking # 386 # 393 # 138 # 166 # 172
Seq. Investment Change TTM 3.94 % 3.42 % 5.83 % -7.91 % 1.07 %
Seq. Net Income Change TTM 18.56 % 10.08 % -46.79 % 6.86 % 14.82 %
Net Income (TTM) in Millions 414 349 317 595 557

HALO Company Profile >> Back to HALO Roi Comparisons >> See Annual HALO Return On Investment



Return On Investment HALO's Ranking
Within: No.
Industry # 8
Sector # 41
Overall # 386

Return On Investment Statistics
High Average Low
43.26 %
-11.78 %
-104.83 %
(Mar 31 2022)   (Dec 31 2013)







Financial Statements
Halozyme Therapeutics Inc's II. Quarter Investments $ 2,233 Millions HALO's Balance sheet
Halozyme Therapeutics Inc's II. Quarter Income $ 230 Millions Quarterly HALO's Income Statement
HALO's Income by Division See HALO's Income by Division


HALO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2,348 1,924 1,621 1,663 987
Y / Y Investment Growth 22.03 % 18.73 % -2.51 % 68.4 % 522.74 %
Net Income in Millions 317 444 282 202 403
Y / Y Net Income Growth -28.64 % 57.71 % 39.31 % -49.81 % 211.97 %
Annual Return On Investment 13.49 % 23.08 % 17.37 % 12.16 % 40.79 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 13.49 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
HALO's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for HALO's Competitors
Subscribers only: Roi for Halozyme Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for HALO's Customers

Other Ratios
HALO's Roa HALO's Inventory Turnover Ratio HALO's Growth Rates HALO's Dividend Statistics
HALO's Profitability Ratios HALO's Asset Turnover Ratio HALO's Dividend Growth
HALO's Roe HALO's Valuation Ratios HALO's Financial Strength Ratios HALO's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %

Date modified: 2026-09-12T06:14:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.